Nirogacestat vs Varegacestat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Desmoid Tumors

Shared mechanism: Gamma-secretase (presenilin complex) · full Desmoid Tumors pipeline

Nirogacestat

Marketed by Merck KGaA and partners

Approved in Desmoid Tumorssmall molecule (gamma-secretase inhibitor)
Reliable signal

NCT03785964 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 142 participants with a hard clinical tumor endpoint, progression-free survival. The primary comparison was statistically significant in favor of nirogacestat: median progression-free survival was not reached with nirogacestat versus 15.1 months with placebo, with HR 0.29 (95% CI 0.15–0.55; p<0.001).

Next expected readout: January 2027 · NCT05879146 (registry estimate)

No aligned efficacy figure on record for this race.

Varegacestat

Developed by Immunome, Inc.

Phase 2/3 in Desmoid Tumorssmall molecule
Partial signal

NCT04871282 · Phase 2/3 · active, not recruiting

This was a randomized, quadruple-masked Phase 2/3 trial with 198 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-12-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Part A: Safety and Tolerability - Adverse Events (Approximately 1.5 years); Part B: Progression free survival (PFS) (Approximately 2 years): Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15). (met)

Result source: NCT04871282

Results for Desmoid Tumors

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nirogacestat: registry results are on file for Desmoid Tumors, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Varegacestat
Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15). NCT04871282 · Phase 2/3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nirogacestat's landscape · Varegacestat's landscape